A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a 10-day course of therapy with orally
administered VCH-759 given at 400-mg, 600-mg or 800-mg three times daily can effectively
reduce the amount of circulating virus (i.e., viral load) in patients with early-stage
chronic hepatitis C-infection. This study will also evaluate the safety and tolerability of
treatment with VCH-759. Blood samples will also be taken to measure the levels of VCH-759
present in plasma at various time points during the treatment period.